NEW YORK, April 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN).Shareholders who purchased shares of GERN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/geron-corporation-loss-submission-form/?id=140988&from=4CLASS PERIOD: February 28, 2024 ...

Core Viewpoint - Securities class action lawsuits have been filed against Geron Corporation for allegedly misleading investors regarding its revenue outlook and product performance during the specified class period from February 28, 2024, to February 25, 2025 [1][2]. Allegations of Misconduct - Defendants allegedly created a false impression of possessing reliable information about Geron's revenue outlook while downplaying risks from seasonality and macroeconomic factors [2]. - Reports regarding the launch success and growth potential of Geron's primary product, RYTELO, were claimed to be overly optimistic and did not reflect the reality of market conditions, competition, and monitoring burdens [2]. - RYTELO reportedly lacked market penetration awareness, hindering Geron's ability to meet the significant unmet need for the drug, especially among first-line patients [2]. - Statements made by the defendants regarding the company's business and prospects were claimed to be materially false and misleading [2]. Lead Plaintiff Process - Investors in Geron have until May 12, 2025, to seek appointment as a lead plaintiff representative or may choose to remain absent class members [3]. - The lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect the ability to share in any recovery [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4]. - The firm aims to protect investors and others from fraud and negligence by businesses [4].

Core Viewpoint - Geron Corporation is facing a class action securities lawsuit due to alleged securities fraud related to the launch and growth potential of its drug Rytelo (imetelstat) between February 28, 2024, and February 25, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Geron misled investors regarding the expectations for Rytelo's market performance, downplaying risks associated with the drug's monitoring requirements and competition [2] - Following the announcement of Geron's fourth-quarter financial results for fiscal 2024 on February 26, 2025, which revealed a flattening growth for Rytelo, the company's stock price dropped from $2.37 to $1.61 per share, a decline of approximately 32.07% in one day [2] Group 2: Investor Actions - Investors who suffered losses during the specified period have until May 12, 2025, to request appointment as lead plaintiff in the lawsuit [3] - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Geron To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Geron between February 28, 2024 to February 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]  NEW YORK  , April 3, 2025 /PRNews ...

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Geron Corporation (NASDAQ: GERN) between February 28, 2024 and February 25, 2025, both dates inclusive (the “Class Period”), of the important May 12, 2025 lead plaintiff deadline. SO WHAT: If you purchased Geron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. W ...

RADNOR, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Geron Corporation (“Geron”) (NASDAQ: GERN) on behalf of those who purchased or otherwise acquired Geron securities between February 28, 2024, and February 25, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is May 12, 2025. ...

NEW YORK, April 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN).Shareholders who purchased shares of GERN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/geron-corporation-loss-submission-form/?id=140405&from=4CLASS PERIOD: February 28, 2024 ...

SAN DIEGO, April 3, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024 and February 25, 2025, both dates inclusive (the "Class Period"), have until Monday, May 12, 2025 to seek appointment as lead plaintiff of the Geron class action lawsuit.  Captioned Dabestani v. Geron Corporation, No. 25-cv-02507 (N.D. Cal.), the Geron class action lawsuit charges Geron and certain of Geron's ...

Core Viewpoint - Geron Corporation is facing a federal securities class action due to alleged failure to disclose material information regarding the launch and growth potential of its lead product candidate, Rytelo, during the specified Class Period [4]. Financial Performance - On February 26, 2025, Geron announced its fourth-quarter financial results for fiscal 2024, revealing that the growth of Rytelo had flattened in recent months. The company attributed this stagnation to seasonality, competition, lack of awareness, and monitoring requirements for the drug treatment [3]. - Following the announcement, Geron's share price dropped by $0.76, from $2.37 on February 25, 2025, to $1.61 on February 26, 2025 [3]. Legal Proceedings - A class action has been filed on behalf of investors who acquired Geron securities between February 28, 2024, and February 25, 2025, with a deadline of May 12, 2025, to seek the role of lead plaintiff [1]. - The complaint alleges that the defendants failed to disclose critical information regarding the expectations for Rytelo's launch and growth potential throughout the Class Period [4].

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our ...